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b-glucocerebrosidase, the enzyme defective in
Gaucher disease, is targeted to the lysosome
independently of the mannose-6-phosphate
receptor. Affinity-chromatography experiments
revealed that the lysosomal integral membrane
protein LIMP-2 is a specific binding partner of
b-glucocerebrosidase. This interaction involves
a coiled-coil domain within the lumenal domain.
b-glucocerebrosidase activity and protein lev-
els were severely decreased in LIMP-2-defi-
cient mouse tissues. Analysis of fibroblasts
and macrophages isolated from these mice
indicated that the majority of b-glucocerebrosi-
dase was secreted. Missorting of b-glucocere-
brosidase was also evident in vivo, as protein
and activity levels were significantly higher in
sera from LIMP-2-deficient mice compared to
wild-type. Reconstitution of LIMP-2 in LIMP-2-
deficient fibroblasts led to a rescue of b-gluco-
cerebrosidase levels and distribution. LIMP-2
expression also led to lysosomal transport of
a b-glucocerebrosidase endoplasmic reticulum
retention mutant. These data support a role
for LIMP-2 as the mannose-6-phosphate-inde-
pendent trafficking receptor for b-glucocere-
brosidase.
INTRODUCTION
Lysosomal proteins are synthesized as soluble or mem-
brane-integrated glycoproteins in the rough endoplas-
mic reticulum (ER). In mammalian cells, mannose-6-phos-
phate receptors (MPRs) mediate the transport of the
majority of lysosomal enzymes to lysosomes. Mannose-
6-phosphate (Man-6-P) terminal residues are recognized
in the trans-Golgi network (TGN) by two MPRs which770 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Incmediate the sorting of lysosomal enzymes from the secre-
tory pathway and deliver them to a prelysosomal compart-
ment from where the receptors return to the TGN and the
ligands are forwarded to dense lysosomes (reviewed in
Kornfeld, 1992; Kornfeld and Mellman, 1989; Ludwig
et al., 1995). It has also been postulated, however, that
alternative MPR-independent mechanisms must exist
for the transport and sorting of a subset of lysosomal
enzymes. This conclusion has been based in part on work
done in I-cell disease (ICD) patient fibroblasts, in which
the lack of addition of Man-6-P moieties to lysosomal en-
zymes results in the strongly increased secretion of many,
but not all, of these enzymes (Ginsel and Fransen, 1991;
Glickman and Kornfeld, 1993; Neufeld, 1991). Additional
support suggesting that some lysosomal enzymes do
not rely on the MPRs has also come from studies done
in MPR-deficient mice (Dittmer et al., 1999; Kasper
et al., 1996; Ludwig et al., 1994).
The lysosomal hydrolase b-glucocerebrosidase (bGC)
is an example of one such enzyme that is unaffected by
perturbations to the MPR-dependent pathway. In fibro-
blasts of ICD patients it has been shown to be intracellu-
larly retained, suggesting that signals other than Man-6-P
are responsible for targeting this enzyme (Aerts et al.,
1988; van Dongen et al., 1985). Mutations within the
gene coding for human bGC are the cause of the most
common lysosomal storage disorder, Gaucher disease,
in which the defective enzyme leads to an accumulation
of glucosylceramide (GlcCer) (Beutler, 1991, 2006). Al-
though the clinical course of this disease has been well
described and an efficient treatment option, enzyme re-
placement therapy, is available, little is known about
how GlcCer accumulation in lysosomes leads to cellular
pathology. Also, the mechanism by which bGC is targeted
from its site of synthesis in the ER to lysosomes is not well
understood.
In the present study, we identified the lysosomal integral
membrane protein type 2 (LIMP-2) as a specific binding
partner for bGC. LIMP-2 is a heavily N-glycosylated 478
residue type III transmembrane protein (Fujita et al.,
1991) comprised of a 400 amino acid lumenal domain,.
two transmembrane domains, and a cytoplasmic domain
of 20 amino acids. Based on homology, LIMP-2 has been
defined as a member of the CD36 family of scavenger
receptor proteins (Febbraio et al., 2001; Krieger, 2001).
We recently showed that overexpression of LIMP-2
caused an enlargement of early endosomes and late en-
dosomes/lysosomes and an impairment of endocytotic
membrane traffic out of the enlarged compartments
(Kuronita et al., 2002, 2005). A deficiency of LIMP-2 inmice
caused ureteric pelvic junction obstruction, deafness, and
peripheral neuropathy (Gamp et al., 2003) associated with
impaired vesicular trafficking and distribution of apically
expressed proteins (Knipper et al., 2006).
We present here in vitro and in vivo evidence that LIMP-
2 acts as a receptor to bind bGC and that the bGC/LIMP-2
complex is transported to the lysosomal compartment in
an MPR-independent pathway.
RESULTS
Isolation and Identification of LIMP-2 as
a b-Glucocerebrosidase-Interacting Protein
The intracellular trafficking and enzymatic activity of bGC,
unlike that of most lysosomal hydrolases, is unaffected in
mouse embryonic fibroblasts doubly deficient for both
MPRs (see Figure S1 in Supplemental Data available
with this article online). In an attempt to identify proteins
involved in the intracellular trafficking of bGC, we em-
ployed an affinity-chromatography approach. A total
detergent-soluble extract of murine liver was passed
over recombinant bGC affinity resin and following exten-
sive washing of the resin-bound proteins were eluted us-
ing pH 4.7 acetate buffer, collected, and then analyzed
by SDS-PAGE and silver staining (Figure 1A). A sample
of the same extract was also passed over a control resin
to which an equimolar amount of BSA had been coupled
to monitor nonspecific background binding of proteins
to the resin. Comparison of the eluates from the two col-
umns revealed that a polypeptide with an apparent mass
of 75 kDa was present in the fractions eluted from the
bGC resin but not the control resin (Figure 1A). To further
evaluate the specificity of this binding candidate for
bGC, a series of small-scale affinity binding reactions
was run in the presence of excess soluble bGC or BSA.
Competition with a 4-fold molar excess of soluble bGC
prevented binding of the 75 kDa polypeptide to the bGC
resin (Figure 1B). Molar excess of BSA had no effect on
75 kDa polypeptide binding. These results further sub-
stantiated that the 75 kDa polypeptide was binding specif-
ically to bGC. To determine the identity of this protein,
fractions from a large-scale bGC-affinity column enriched
in the 75 kDa polypeptide were resolved by SDS-PAGE
and the band of interest was excised, in-gel digested
with trypsin, and sequenced using nano-LC-MS/MS.
Based on the amino acid sequences obtained, the poly-
peptide was identified as the lysosomal integral mem-
brane protein LIMP-2. PNGase-F treatment to remove
N-linked carbohydrates resulted in a mobility shift of thisCpolypeptide from 75 kDa to 54 kDa (Figure 1C), which is
themolecular mass calculated for deglycosylated LIMP-2.
The Lumenal Domain of LIMP-2 Is Required for
Association with b-Glucocerebrosidase
bGC resides in lysosomes as a protein associated with the
lumenal membrane (Rijnboutt et al., 1991). Topologically,
the lumenal portion of the LIMP-2 polypeptide is also ex-
pected to be in close proximity to this membrane (Okazaki
et al., 1992). Therefore, we investigated whether this re-
gion in LIMP-2 might be responsible for the association
with bGC. Recombinant fusion-tagged LIMP-2 lumenal
domain protein (L2LD) encompassing residues 27–432
was expressed as a soluble protein, purified, and then
used in an in vitro pull-down assay with bGC (Figure 1D).
bGC bound specifically to L2LD, indicating that the
lumenal domain of LIMP-2 is sufficient for the interaction
and that the binding between these two proteins is direct.
We also investigated whether the corresponding lumenal
region of CD36 (CD36LD) might have the capacity to
bind bGC in this assay, as CD36 and LIMP-2 share
34% overall sequence identity, the majority of which is
found across the lumenal domain (Figure 1D). No binding
of CD36LD was detected, indicating that the interaction of
bGC with LIMP-2 likely depends on features unique to the
LIMP-2 lumenal domain. When a similar in vitro pull-down
assay was performed using recombinant fusion-tagged
LIMP-2 cytoplasmic domain protein or the isolated N- or
C-terminal halves of the lumenal domain (residues
27–155 or 155–432), no binding of bGC was detected
(data not shown). These data support a scenario in which
domains of LIMP-2 and bGC could interact within the lu-
men of some or all of the secretory compartments in which
they coexist.
Our efforts to isolate and identify LIMP-2 from tissue ex-
tracts revealed that full-length endogenous LIMP-2 could
be released effectively from bGC affinity resin by elution
with buffers at lysosomal pH. bGC passes through intra-
cellular compartments of varying pH en route from its
point of synthesis in the ER to its final destination in lyso-
somes. To determine compartments in which the associ-
ation or dissociation of LIMP-2 and bGC may occur, the
ability of bGC affinity resin to bind L2LD over a range of
pH values was tested via small-scale in vitro binding re-
actions (Figure 1E). Binding of L2LD to the bGC resin
was favored at neutral pH and attenuated as the pH
approached that typical of the lysosomal lumen. This
suggested that the most probable points of bGC and
LIMP-2 association are prelysosomal, possibly beginning
in compartments as early as the ER or Golgi apparatus.
Effects of LIMP-2 Deficiency on
b-Glucocerebrosidase Activity, Expression,
and Localization
Our in vitro binding data support a situation in which bGC
and LIMP-2 interact directly within intracellular trafficking
compartments of cells. To further test this hypothesis,
we explored the effects of LIMP-2 deficiency in theell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 771
Figure 1. The Lysosomal Integral Mem-
brane Protein 2 (LIMP-2) Binds Specifi-
cally to Recombinant b-Glucocerebrosi-
dase
(A) Affinity chromatography: the arrowhead in-
dicates the migration of the 75 kDa GC binding
protein.
(B) Binding behavior of the 75 kDa GC binding
protein (LIMP-2) in the presence of soluble b-
glucocerebrosidase competition. Buffer or to-
tal detergent-soluble murine liver extract was
mixed with either BSA-agarose resin (BSA) or
GC-agarose resin (GC). In some reactions,
a 4-fold molar excess of either soluble BSA
or GC was added as a negative control for
competition (mock) or specific competition
(comp), respectively. A lane showing the total
starting liver extract used in these reactions is
also shown (extract). The arrowhead indicates
the 75 kDa binding protein, and the asterisk
indicates a small amount of bGC leached
from the column.
(C) The 75 kDa GC binding protein in the pres-
ence (+) or absence () of PNGase-F.
(D) bGC binds the lumenal domain of LIMP-2
but not of CD36. Purified recombinant fusion-
tagged lumenal domain of either LIMP-2 (L2-
LD) or CD36 (36-LD) was mixed with a fusion
tag-specific affinity resin on its own as a posi-
tive control for a tag-based pull-down assay,
or comixed with soluble bGC (GC) and the
tag-specific affinity resin to assess specific in-
teraction with bGC (see diagram). Following
extensive washing, bound proteins were eluted
and analyzed. Left panel: half the total load
amount for each reaction is shown. Right
panel: the results for the binding of bGC alone
(GC) and those for the binding of tagged L2-LD
alone (L2-LD) and tagged CD36 alone (36-LD)
are shown as negative and positive controls
for tag-based capture, respectively. Cocapture
of GC in the presence of tagged L2-LD is
shown (L2-LD + GC). No cocapture of GC is
seen in the presence of 36-LD (36-LD + GC).
The arrowhead indicates themigration position
of bGC.
(E) Effect of pH on the association of bGC and
the lumenal domain of LIMP-2. Binding reac-
tions using bGC affinity resin and soluble L2-
LD were set up in a series of buffers ranging
from pH 4.5 to 8.5. Following incubation, the resin was washed in buffer of the same pH as used in each respective binding reaction, and then
any bound L2-LD protein was eluted in Laemmli buffer and analyzed by SDS-PAGE and Coomassie staining. The arrowhead indicates the migration
of L2-LD.LIMP-2 knockout (KO) mouse to determine whether there
might be bGC-specific consequences. We evaluated bGC
activity levels in total tissue homogenates from wild-type
and LIMP-2 KO mice (Figure 2A). The activity of another
lysosomal hydrolase, a-galactosidase, which does not
bind the lumenal domain of LIMP-2 in in vitro assays
(data not shown), was also assayed for comparison
(Figure 2B). bGC activity was significantly decreased in
all of the KO tissue samples relative to wild-type; this dif-
ference was most notable in liver, where the average de-772 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Inccrease was greater than 75% (Figure 2A). In contrast,
such a reduction was not seen when the activity of a-
galactosidase was measured in the same samples. Im-
munoblotting revealed a very significant and consistent
decrease in the levels of bGC protein in each of four KO
liver samples compared to wild-type (Figure 2C, right
panel). Anti-bGC immunoblots of kidney homogenates
prepared from these same animals yielded identical
results (Figure 2C, left panel). To determine whether the
reduced expression level was because of changes at the.
transcription level, we performed a northern blot analysis
of RNA derived from liver and kidney of wild-type and
LIMP-2 KO mice. The bGC transcript levels were not sig-
nificantly different between the two genotypes (Figure 2D),
suggesting that the decrease in bGC protein expression
was a result of posttranscriptional events.
The differences in bGC enzyme activity detected be-
tween LIMP-2 wild-type and KO tissues are almost cer-
tainly a reflection of the drop in total bGC protein levels,
a conclusion that is further substantiated by immunohisto-
chemical staining (Figure 2E). Spleen (not shown) and liver
sections of WT and LIMP-2 KO mice were stained for
LIMP-2 (Figures 2Ea and 2Eb), bGC (Figures 2Ec and
2Ed), and LAMP-1 (Figures 2Ee and 2Ef). In wild-type tis-
sues as exemplified by liver, LIMP-2 and bGC colocalized
with LAMP-1 in lysosomes, whereas in LIMP-2 KO tissue,
neither LIMP-2 nor bGC staining was visible. However, the
levels and subcellular distribution of LAMP-1 in KO tissue
appeared normal, indicating that the integrity of the lyso-
somal compartment is maintained in LIMP-2-deficient
tissue. In a wide spectrum of tissues, a tight correlation
between the relative levels of bGC and LIMP-2 protein
was detected such that in samples in which LIMP-2 was
absent, bGC was deficient, but in samples in which
LIMP-2 was present, bGC was readily detectable
(Figure S2).
Reduction of lysosomal bGC levels has been found to
correlate with an increase in the bGC substrate GlcCer
in Gaucher disease (Brady et al., 1965; Nilsson et al.,
1985; Nilsson and Svennerholm, 1982). Analysis of GlcCer
levels in tissues isolated from wild-type and LIMP-2 KO
mice revealed an almost 2-fold increase of GlcCer in the
liver and lung from LIMP-2-deficient animals compared
to normal (Table 1).
LIMP-2-Deficient Lysosomes Are Depleted of
b-Glucocerebrosidase
To more precisely define the molecular events leading to
the reduction in bGC activity levels in LIMP-2 KO tissues,
we examined the status of bGC inmouse embryonic fibro-
blast (MEF) cells derived from wild-type and LIMP-2 KO
embryos. Both the activity (Figure 2F) and the level of
bGC protein (Figure 2G) were dramatically reduced in
the extracts from LIMP-2 KO MEF cells. Immunostaining
for bGC in MEFs revealed that in WT cells, bGC localized
in LAMP-2-positive lysosomal compartments, whereas in
LIMP-2 KO MEF cells (Figure 2H) or HeLa cells with an
siRNA-mediated downregulation of LIMP-2 (Figure S3),
almost no lysosomal bGC could be detected. Although
in a minority of LIMP-2 KO MEF cells a very weak lyso-
somal bGC staining was still detectable (not shown), in
the majority of these cells it appeared that most if not all
the bGC had been secreted. Overexpression of bGC in
LIMP-2 KO cells revealed that bGC is retained in the ER
and unable to be delivered to the lysosomal compartment
(Figure S4).
Given the dramatic effects of LIMP-2 deficiency on the
status of bGC in cells, we investigated whether LIMP-2Cwas directly required for the correct lysosomal localization
of bGC. For this we transfectedmyc-taggedmurine LIMP-
2 into LIMP-2 KOMEF cells and assessedwhether LIMP-2
expression could rescue the mislocalization of bGC.
Transfected cells could easily be identified by staining
with antibodies against the lumenal domain of LIMP-2
(not shown) or against the myc epitope (Figures 3A–3C).
In 95% of LIMP-2-transfected cells, but not in LIMP-2
KO cells transfected with another lysosomal membrane
protein (LAMP-2; data not shown), the bGC expression
level could be rescued to wild-type levels (see Figure 2Ha)
and bGC colocalized with LIMP-2 in lysosomal compart-
ments (Figure 3C). The juxta-membrane localization of
both LIMP-2 and bGC is demonstrated by their ring-like
stainingpattern in the intracellular vesicles. A triple staining
with LIMP-2, bGC, and LAMP-2 (Figures 3D–3G) con-
firmed the correct lysosomal sorting of bGC after LIMP-2
re-expression. Immunoblot analysis after transient trans-
fection of LIMP-2 in KO MEF cells confirmed the micro-
scopical results. Expression of LIMP-2 led to an increase
in the general bGC level and in the mature, most likely
lysosomal, form of bGC (Figure 3H).
The requirement of LIMP-2 for the lysosomal localiza-
tion of bGC was also supported by an additional experi-
ment in COS cells in which LIMP-2 expression enabled
the efficient delivery of bGC to the lysosomal compart-
ment, but the fusion of LIMP-2 to a strong ER retention
motif (Zerangue et al., 2000) prevented the transport of
bGC out of the ER (Figures 4A–4F). Coimmunoprecipita-
tion confirmed the association of LIMP-2 and bGC as
well as the association of the LIMP-2 ER retention mutant
with bGC (Figures 4G and S5A), again suggesting that
binding of these proteins can occur in compartments as
early as the endoplasmic reticulum. We also tested the
expression in COS cells of a truncated version of LIMP-2
(LIMP-2 [ld]) in which the lumenal domain was fused to
the bGC signal peptide to target it to the extracellular
space. LIMP-2 (ld) was found to be secreted. Coexpres-
sion of this LIMP-2 construct with bGC led to a dramatic
increase in the amount of bGC secreted compared to
that seen upon the expression of bGC on its own (Fig-
ure S5B). Such an increase was not seen when wild-type
LIMP-2 was coexpressed with bGC. These data provided
additional evidence for the association of these proteins.
A Coiled-Coil Motif within the Lumenal
Domain of LIMP-2 Is Needed for
b-Glucocerebrosidase Binding
The isolated halves of the LIMP-2 lumenal domain (resi-
dues 27–155 and 155–432) do not bind bGC (data not
shown). This suggested to us that a region around amino
acid residue 155 might be required for the bGC-LIMP-2
association. Exploring this hypothesis, we discovered
a conserved coiled-coil domain of LIMP-2 from amino
acid residues 150–167 (Figures 5A and 5B). When we dis-
rupted the putative coil-coiled domain by deleting this
region (LIMP-2Dcc) or by replacing a leucine by a proline
at amino acid position 160 (LIMP-2-L160P), the resultantell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 773
Figure 2. Decreased b-Glucocerebrosidase Activity and Protein Expression in LIMP-2-Deficient Mice
(A) bGC activity was determined in tissue extracts fromwild-type and LIMP-2 KO liver, spleen, brain, and lung from 4-month-oldmice (n = 4 each). The
percentage of activity in the KO tissues relative to wild-type (100%) is shown.
(B) a-galactosidase activity was determined in tissue extracts from wild-type and LIMP-2 KO liver, spleen, brain, and lung from the same samples as
used in (A).
(C) Decreased expression level of bGC revealed by immunoblot analysis in LIMP-2 KO kidney and liver samples. Normalized loads from four wild-type
and four LIMP-2 KO animals were resolved by SDS-PAGE, blotted to PVDF, and probed with an antibody specific to bGC.
(D) Northern blot analysis of bGC transcript levels in liver, kidney, and MEF samples (upper panel). As a loading control, glyceraldehyde phosphate
dehydrogenase mRNA levels are shown (GAPDH; lower panel).
(E) Immunohistology for LIMP-2, bGC, and LAMP-1 in liver from a control (a, c, and e) and a 3-month-old LIMP-2 KO mouse (b, d, and f). Staining for
LIMP-2 shows complete absence of immunoreactivity in LIMP-2 KO liver (b). bGC immunoreactivity is almost completely lost in LIMP-2 KO liver (d).774 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc.
mutants failed to rescue lysosomal bGC expression in
LIMP-2-deficient MEF cells despite the fact that both mu-
tants were, like wild-type LIMP-2 (Figure 5A), delivered
normally to the lysosomal compartment (Figures 5C and
5D). Coimmunoprecipitation analysis indicated that the
physical interaction between endogenous bGC and
LIMP-2 was lost in the case of both mutants (Figure 5E).
In vitro pull-down experiments using purified recombinant
proteins further confirmed the lack of bGC binding to the
LIMP-2-L160P mutant (data not shown). Taken together,
these results strongly suggest that the LIMP-2 region
from residues 150–167 is crucially involved in the binding
of LIMP-2 to bGC.
LIMP-2 Expression Leads to Lysosomal
Localization of a Clinical Glucocerebrosidase
Mutant Normally Retained in the
Endoplasmic Reticulum
To analyze whether any of the more common clinical
mutations within bGC affected binding to LIMP-2, we
expressed bGC N370S, G202R, and L444P and analyzed
the interaction of LIMP-2 and these mutant proteins in our
in vitro binding assay. None of these mutations in bGC ab-
rogated the binding to LIMP-2 (Figure S6). Interestingly,
however, we observed that LIMP-2 expression led to
transport of bGC L444P, a known ER retention mutant
(Schmitz et al., 2005), to the lysosomal compartment
(Figure 5F), suggesting that LIMP-2 can bind bGC within
the endoplasmic reticulum and that an increase in LIMP-
2 expression may be sufficient to overcome the ER reten-
tion of specific Gaucher mutants. Interestingly, the ER
localization of another clinical bGC mutant, P415R, was
not altered after overexpression of LIMP-2 (Figure S6B),
Table 1. Analysis and Comparison of
Glucosylceramide Substrate Levels in Tissues from
Wild-Type and LIMP-2 Knockout Mice
Tissue
LIMP-2
Genotype
GlcCer
(ng/mg Tissue)
Standard
Deviation
Liver WT 47 11
KO 88 21
Lung WT 53 11
KO 98 11
Liver and lung tissue samples (n = 4 for each) were analyzed
for GlcCer substrate levels utilizing a mass spectrometry-
based assay (see Experimental Procedures).Csuggesting a direct or indirect effect of this mutation on
binding to LIMP-2.
b-Glucocerebrosidase Is Mistargeted In Vitro
and In Vivo
Because MPR-deficient mice and I-cell disease patients
exhibit increased levels of several lysosomal enzymes in
their serum, we examined whether an analogous observa-
tion might be made for bGC in the serum of LIMP-2 KO
mice. Sera from wild-type and LIMP-2 KO mice were col-
lected and total normalized protein samples were ana-
lyzed for bGC levels by immunoblot. Whereas no bGC
was found in the sera of wild-type mice, a significant level
of bGC was observed in the serum from LIMP-2 KO mice
(Figure 6A). This observation corresponded with an
approximately 11-fold increase in bGC activity in the
sera from LIMP-2 KO animals (Figure 6B) compared to
that in wild-type mice. These results provide in vivo evi-
dence that a lack of LIMP-2 leads to the mistargeting of
bGC to the extracellular space. To investigate this mistar-
geting in isolated LIMP-2 KO cells, we incubated wild-type
and LIMP-2 KO macrophage preparations in serum-free
medium for 24 hr and analyzed bGC levels in cell extracts
and culture supernatants (Figure 6C). In agreement with
our in vivo observations, we observed a significant in-
crease in bGC protein levels in the culture supernatants
of LIMP-2 KOmacrophages. In wild-type cells, only about
5%–7% of the total bGC was found to be secreted. In
LIMP-2 KOmacrophages, between 46% and 47% of total
bGCwas found in themedium (Figure 6D). Similar findings
were made in MEF cells, which also showed a large in-
crease in the secretion of bGC in the absence of LIMP-2
(Figure S7). Using PNGase-F digestion, we observed
that the molecular weight of intracellular bGC was re-
duced from 54 kDa to about 50 kDa in both wild-type
and LIMP-2 KO MEF cells (Figure 6E). EndoH treatment,
which does not affect glycosylated proteins that have
passed the Golgi apparatus, revealed that in wild-type
MEF cells more than 90% of the bGC was EndoH resis-
tant, indicating that it has left the ER. In contrast, the
same EndoH treatment in LIMP-2 KO MEF cells, despite
a lower overall bGC protein level, led to a complete diges-
tion of the bGC carbohydrates, suggesting that residual
bGC in the absence of LIMP-2 is trapped in the ER.
Pulse-chase experiments in HeLa cells depleted of
LIMP-2 using siRNA allowed us to examine the fate of
bGC over time under conditions of LIMP-2 deficiency
(Figure 6F). Whereas in mock treated cells bGC starts to
become EndoH resistant after 30–60 min indicating it
has left the ER, LIMP-2 siRNA treatment leads to ERLAMP-1 staining shows lysosomal structures in wild-type (e) and LIMP-2 KO liver (f). Insets showmagnification of merged images of GC and LAMP-1
staining demonstrating lysosomal localization of GC in wild-type but not in LIMP-2 KO hepatocytes. The scale bars represent 50 mm.
(F) Specific bGC activity (mU/mg protein) was determined in extracts of two independent wild-type (+/+) and LIMP-2 KO (/) MEF cell lines.
(G) Top panel: decreased bGC levels in four independent LIMP-2 KOMEF cell lines as compared to wild-type cells. Middle panel: tubulin expression
as a loading control. Lower panel: LIMP-2 expression.
(H) Immunofluorescence labeling of LAMP-2 (in red) and bGC (in green) in wild-type (a and b) and LIMP-2 KO (c and d) MEF cells. A merged image is
presented. Right panels showmagnified views of boxed regions in (a) and (c). The scale bars in (a) and (c) represent 10 mm, and in (b) and (d) represent
1 mm. bGC is absent from lysosomes lacking LIMP-2.ell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 775
Figure 3. Reconstituted Transport of b-Glucocerebrosidase
to Lysosomes after Re-expression of LIMP-2 in LIMP-2-Defi-
cient MEF Cells
LIMP-2 KO MEF cells were transiently transfected with a myc-tagged
mouse LIMP-2 expression vector.
(A) LIMP-2 staining.
(B) bGC staining.
(C) Merged image showing an almost complete colocalization of
LIMP-2 and GC. The asterisks indicate MEFs not transfected, which
exhibit only a trace amount of GC.
(D–G) Triple-labeling experiment showing the rescue of bGC lysosomal
localization.
(D) LIMP-2 labeling.
(E) bGC labeling.
(F) LAMP-2 labeling.
The scale bars in (A)–(F) represent 10 mm.776 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc.retention until 120 min of chase and a dramatic reduction
in intracellular bGCbetween 120 and 480min (Figures 6Fa
and 6Fc). This drop correlated with the missorting of bGC
into the cell culture supernatant between 120 and 480 min
(Figures 6Fb and 6Fc). In contrast, the processing and se-
cretion of cathepsin D was not affected by the downregu-
lation of LIMP-2 (data not shown). Proteasomal degrada-
tion of bGC in the absence or downregulation of LIMP-2
was excluded, as inhibition of the proteasome did not alter
bGC protein levels (Figure S8).
Taken together, these experiments show that LIMP-2 is
required for the intracellular retention of bGC and that
a failure to bind LIMP-2 leads tomistargeting and amarked
increase in the secretion of bGC.
DISCUSSION
In the present study, we have identified an unexpected
role for LIMP-2 as a sorting receptor required for the deliv-
ery of b-glucocerebrosidase to lysosomes. The Man-6-P-
receptor pathway has been very well characterized as
a major route for the sorting of lysosomal enzymes; how-
ever, the mechanism for the intracellular targeting of bGC
to lysosomes has been unclear until now.
Our findings that bGC associates with LIMP-2, that
these proteins colocalize in intracellular vesicular com-
partments, and that the activity, levels, and localization
of bGC exhibit a dramatic correlation with the presence
or absence of LIMP-2 reveal that bGC independence of
M6P-based sortingmechanisms is almost certainly a con-
sequence of its routing via LIMP-2 through the lysosomal
membrane protein delivery pathway. Lysosomal mem-
brane proteins, in contrast to soluble M6PR binding lyso-
somal proteins, are directed from the Golgi to lysosomes
after incorporation into clathrin-coated vesicles by virtue
of the interaction of distinct targeting motifs in their cyto-
plasmic tails with multimeric adaptor proteins; in the
case of LIMP-2, an association with AP-3 (Honing et al.,
1998) and AP-1 (Fujita et al., 1999) has been suggested.
The evidence that the association of bGC and LIMP-2 is
sensitive to changes in the range of pH values foundwithin
the intracellular compartments through which these
proteins pass is also consistent with a model for LIMP-
2-based trafficking (Figure 7). Preliminary crosslinking
experiments (data not shown) with LIMP-2 and bGC coex-
pressed in COS cells suggest that the protein-protein
complex is about 250 kDa in size, which would fit with
a 2:2 bGC:LIMP-2 stoichiometry (Figure 7, insert). These
data support a scenario in which LIMP-2 and bGC would
associate in the ER at more neutral pH and subsequently
dissociate in the lysosome at more acidic pH. Such an
(G) Merged image of (D)–(F) showing colocalization of bGC and
LAMP-2/LIMP-2. The scale bar represents 5 mm.
(H) Mouse LIMP-2 (mLIMP-2) was transfected (+) in wild-type (+/+) and
LIMP-2 KO (/) MEF cells and compared to nontransfected () cells
by immunoblot analysis. bGC, mLIMP-2, and a-tubulin (loading
control) expression are presented.
Figure 4. Mistargeting of LIMP-2 Alters
the Localization of b-Glucocerebrosi-
dase
(A–F) COS7 cells (A–F) were cotransfected with
LIMP-2-myc and bGC-HA expression con-
structs, and after transfection were stained
with anti-myc antibodies to detect LIMP-2
wild-type protein (A) or the LIMP-2mutant con-
taining a strong ER retentionmotif (B) or with an
anti-HA antibody to detect the tagged bGC
protein (C and D).
(E and F) Merged images. The asterisks indi-
cate nontransfected cells. The scale bars
represent 10 mm.
(G) LIMP-2-myc (L2) or LIMP-2-myc containing
an ER retention signal (L2ret) were expressed
in COS7 cells. Pull-down assay with anti-myc
(LIMP-2) antibodies (+) led to coimmunopreci-
pitation of bGC; pull-down assay in the ab-
sence of LIMP-2 antibodies (). Upper panel:
anti-myc (LIMP-2 detection); lower panel:
anti-human bGC detection (crossreacts with
endogenous bGC).early association is supported by our coimmunoprecipita-
tion experiments, in particular after expression of a LIMP-2
ER retention mutant. Interestingly, we also observed that
a clinical mutant of bGC, L444P, which is usually retained
in the ER, can be shifted to the lysosomal compartment
after coexpression of LIMP-2. These data not only suggest
that an increase in LIMP-2 levels may be of some thera-
peutic interest for selected bGC mutations but also sup-
port our other data demonstrating that interaction can
occur in the endoplasmic reticulum. When the fate of
newly synthesized bGC was monitored in the absence of
LIMP-2, we observed that bGC release from the ER was
retarded before bGC was missorted and secreted, sug-
gesting that LIMP-2 binding to bGC is needed for efficient
ER exit toward the lysosomal compartment. bGC secre-
tion in the absence of LIMP-2 is also substantiated by
our experiments with proteasomal inhibitors, which did
not affect the rapid intracellular loss of bGC (Figure S8).
In contrast to lysosomal delivery of M6PR-targeted pro-
teins or proteins such as the major histocompatibility
complex II through the binding of the invariant chain(Trombetta and Mellman, 2005), where diversion from
the constitutive secretory pathway occurs after leaving
the trans-Golgi network (Kornfeld, 1992) (Figure 7), it ap-
pears that lysosomal bGC trafficking requires LIMP-2
binding already taking place in the ER. Our observation
that modulation of carbohydrates has no effect on the
association of both proteins (data not shown) also sub-
stantiates association in the ER. It is also conceivable
that the early association of both proteins generates a
signal for sorting within the TGN.
bGC associates with membranes in a carbohydrate-
independent manner (Aerts et al., 1988; Leonova and
Grabowski, 2000), and this persists from the ER through
lysosomes (Rijnboutt et al., 1991). Interestingly, we found
that overexpression of LIMP-2 in COS cells significantly
enhanced the membrane association of coexpressed
bGC compared to the expression of bGC on its own
(Figure S9), further emphasizing the importance of the
LIMP-2/bGC interaction in vesicular compartments. Our
data also revealed that the binding of LIMP-2 and bGC
appeared to be stable during transport through the GolgiCell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 777
Figure 5. Analysis of LIMP-2 and b-Glucocerebrosidase Binding
(A) Rescue of lysosomal bGCexpression after transfection of wild-type (wt) LIMP-2, which demonstrates high coiled-coil probability from amino acids
150–167 (inset) in LIMP-2 KO MEFs.
(B) Multiple species sequence alignment of LIMP-2. The gray box highlights the conserved coiled-coil domain and (a)–(g) indicate the residues in the
helix, with hydrophobic residues presented in bold.
(C and D) No rescue of lysosomal bGC expression after transfection of LIMP-2-Dcc (C) or LIMP-2-L160P (D) in LIMP-2 KO MEFs.
Disruption of the coiled-coil probability is shown in the insets. Coiled-coil probabilities within the lumenal domain of (A) LIMP-2wt, (C) LIMP-2-Dcc,
and (D) LIMP-2-L160P were determined with the program Coils (version 2.2). The x axes represent the amino acid position, whereas the y axes illus-
trate the coiled-coil probability. Single labeling is shown in the black and white images. Merged images of LIMP-2 and bGC staining are shown in
colored images of (A), (C), and (D). The scale bars in (A), (C), and (D) represent 10 mm.
(E) Coimmunoprecipitation analysis after pull-down assay with anti-myc (LIMP-2) antibodies. After transfection of myc-tagged LIMP-2 and LIMP-2
mutants (LIMP-2 Dcc, LIMP-2 L160P, and LIMP-2 ERret; lower panel), binding to endogenous bGC (upper panel) was analyzed.
(F) bGCmutant (L444P) is retained in the ER after transfection in COS7 cells (a). Coexpression of LIMP-2 leads to the lysosomal transport of this mu-
tant (b–d). Colored images (a and d) present the merge of bGC and LIMP-2 stainings. Single stainings (b and c). The asterisks indicate untransfected
cells. The scale bars represent 10 mm.apparatus, as expression of a secreted LIMP-2 mutant
also led to a significant missorting and consequent in-
crease of secreted bGC. Moreover, it seems unlikely that778 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Inca defect in endocytosis of bGC underlies the increased
extracellular levels of the enzyme, as uptake of iodinated
bGC in LIMP-2 KO cells is unimpaired (data not shown)..
It is still unclear whether LIMP-2 might, similarly to the
M6PR, also recycle back from endosomes to theGolgi ap-
paratus, and we cannot completely rule out the possibility
that other lysosomal proteins might also bind to LIMP-2 at
this point. The results from our affinity-chromatography
experiments with mouse liver extract and the lack of
LIMP-2 association with a-galactosidase and a-glucosi-
dase (data not shown), however, highlight a rather specific
nature for the LIMP-2/bGC interaction. LIMP-2 is homolo-
gous to CD36 and defines it as a member of the CD36-
scavenger receptor-like protein family (Vega et al.,
1991). Despite the fact that LIMP-2 and CD36 share
34% sequence identity over their lumenal domains, we
found that bGC did not bind to this region of CD36 under
conditions in which it bound the corresponding region in
LIMP-2. Thrombospondin 1 (TSP-1), however, has been
demonstrated to bind both CD36 and LIMP-2 (Asch
et al., 1987; Crombie and Silverstein, 1998). The differing
ability of these two family members to bind bGC suggests
that, as a ligand, bGC has an apparently higher level of
specificity for LIMP-2 than does TSP-1. Because LIMP-2
is predominantly localized on intracellular membrane-
bound compartments and exhibits only low levels of cell-
surface expression (Okazaki et al., 1992; Suarez-Quian,
1987), it is possible that the interaction between LIMP-2
and TSP-1 does not predominate in the physiological set-
ting, particularly given that TSP-1 is found in the matricel-
lular environment. It may be that there are two subtypes to
the CD36 family: proteins such as LIMP-2 which function
intracellularly, and others like CD36 that preferentially
act at the plasma membrane.
Our binding studies indicate that bGC interacts with
a coiled-coil domain in the lumenal domain of LIMP-2.
The disruption of the coiled-coil domain abolished inter-
action with bGC yet allowed normal expression and lyso-
somal transport of these LIMP-2 mutants. Coiled-coil do-
mains have been shown to be involved in protein-protein
interaction (Lupas et al., 1991), and our experiments
revealed a critical role of this domain in LIMP-2 for bGC
binding. A more detailed structural analysis, however,
will be necessary to completely resolve the nature of the
binding of both proteins.
A large variety of mutations that occur in the gene
encoding bGC result in the accumulation of its substrate
glucosylceramide (GlcCer) and consequently lead to
Gaucher disease in humans (for a review, see Sidransky,
2004). Manifestation of this disease is typically a result
of a deficiency in enzyme activity, inappropriate bGC lo-
calization, decreased bGC stability, or a combination of
these factors (Beutler and Kuhl, 1986; Liou et al., 2006;
Schmitz et al., 2005). We found that the levels of GlcCer
substrate were elevated in LIMP-2-deficient liver and
lung but apparently unaffected in other tissues, namely
kidney, spleen, and brain (data not shown). Such tissue-
specific differences could result from differences in sub-
strate availability or utilization in each tissue; alternatively,
they could be because of varying amounts of residual bGC
activity which may be sufficient to prevent GlcCer accu-Cmulation to levels at which more significant Gaucher-like
pathologies might be seen. Despite the absence of robust
Gaucher-like phenotypes in LIMP-2 KO mice, it is none-
theless interesting to speculate that some of the diversity
in Gaucher phenotypes observed in humans carrying
identical bGC mutations might result from secondary
mutations in the LIMP-2 pathway.
We observed that, in contrast to themore common bGC
disease-related mutant L444P which, like the N370S and
G202R mutants, still bound to the LIMP-2 lumenal do-
main, the bGC mutant P415R could not be transported
to lysosomes after coexpression with LIMP-2, suggesting
that this mutation directly or indirectly affects the binding
site for LIMP-2. Structural analyses of the LIMP-2/bGC
complex will be required to evaluate the importance of
this bGC region for LIMP-2 binding.
In conclusion, we have identified a function for LIMP-2
as a Man-6-P-independent trafficking receptor for bGC.
The discovery of this function helps link together many
of the details from previous studies of both LIMP-2 and
bGC biology and, importantly, helps clarify the role pro-
posed for LIMP-2 in the biogenesis and maintenance of
lysosomes. The nature of how the interaction between
these two proteins is mediated, whether there are addi-
tional cargoes for LIMP-2, and how this finding plays
into the realm of LIMP-2- and bGC-related pathologies
will be exciting subjects for future studies.
EXPERIMENTAL PROCEDURES
Cell Lines and Mice
Mouse embryonic fibroblasts from LIMP-2-deficient and wild-type
mice generated from E12.5 embryos and primary cell lines between
passages 3 and 6 were used for the experiments. For rescue experi-
ments, cells were transiently transfected using Fugene 6 (Roche,
Mannheim, Germany). Primary macrophages were isolated from mice
4 days after peritoneal injection of 4% thioglycolate (Huynh et al.,
2007). Wild-type and LIMP-2-deficient mice (Gamp et al., 2003) were
maintained in a conventional animal facility. All experiments were
performed with approval of the National Animal Care Committee of
Germany.
Plasmids, Expression, and Purification of Recombinant
Proteins
Expression plasmids for LIMP-2, bGC, and CD36 were generated as
described in Supplemental Data. For protein expression in the BEV
system, Tn-5 cells (Expression Systems, Woodland, CA, USA) were in-
fected with recombinant virus at a multiplicity of infection (MOI) = 1.
Conditioned medium was harvested 48 hr postinfection by centrifuga-
tion at 500 3 g and 0.22 mm filtered. Proteins expressed as fusions to
the 12 amino acid HPC4 epitope tag were purified from the medium
as described by Rezaie et al. (1992). Recombinant human bGC was
purified as we previously described (Sawkar et al., 2006).
Affinity Chromatography and Binding Assays
Purified recombinant bGC was covalently coupled to CNBr-activated
Sepharose 4B (Sigma Chemical, St. Louis, MO, USA) as described
by Reczek et al. (1997) or coupled using the AminoLink immobilization
kit (Pierce, Rockford, IL, USA). Mouse tissue extracts were prepared
from frozen tissues (Pel-Freeze Biologicals, Rogers, AR, USA) and
small-scale affinity-chromatography experiments performed essen-
tially as described (Reczek et al., 1997). For large-scale affinityell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 779
Figure 6. Missorting of b-Glucocerebrosidase in the Absence of LIMP-2
(A) Secretion of bGC in the serum of LIMP-2 KO mice. Immunoblot analysis of bGC of serum samples taken from 6-month-old mice. The lower panel
shows equal protein loading (Coomassie stain).
(B) Activity of bGC in the sera of wild-type mice and LIMP-2 KO mice (11-fold increase in bGC activity). Error bars indicate the standard errors of the
means.
(C) Primary macrophages from wild-type and LIMP-2 KO mice were immunoblotted for bGC (upper panel) and LIMP-2 (lower panel).
(D) Densitometric quantification of the experiment in (C) representing the percentage of bGC secreted into the culture medium.780 Cell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc.
Figure 7. Model for Mannose-6-Phos-
phate-Independent Targeting of b-Glu-
cocerebrosidase by LIMP-2
The preferential binding of bGC to LIMP-2
(binding complex is highlighted in inset) at
more neutral pH suggests these two proteins
associate in secretory compartments as early
as the ER or Golgi apparatus, from where
they then progress to distal, more acidic prely-
sosomal compartments (LE, late endosomes)
and eventually to dense lysosomes (LYSO).
At the lower pH of these compartments, bGC
may dissociate from LIMP-2. Yellow arrows,
LIMP-2 pathway. The M6P-receptor pathway
(white arrows) is shown for comparison.chromatography, bound proteins were eluted from the coupled resin in
50 mM sodium acetate (pH 4.7), 1 M sodium chloride. Antibody-based
pull-down experiments were done using a monoclonal antibody to the
HPC4 epitope covalently coupled to NHS-activated Sepharose 4 Fast
Flow resin (AP-Biotech, Little Chalfont Buckinghamshire, UK). Resin
was incubated with solutions of HPC4 epitope-tagged proteins, or
non-epitope-tagged proteins as controls, or with a mixture of epi-
tope-tagged protein and proteins to be tested for binding by cocapture
in buffers containing 1 mM calcium chloride to allow for the calcium-
dependent HPC4 epitope-antibody interaction. Five to tenmicrograms
of each protein was used per reaction. Following extensive washing in
the presence of 1 mM calcium chloride, HPC4-tagged and cocaptured
proteins were eluted in buffer containing 5 mM EDTA in place of
calcium chloride and the sample was analyzed by SDS-PAGE.
Enzyme Activity Assays, PNGase-F, EndoH Treatment, and
GL1-Substrate Analysis
The 4MU-based activity or colorimetric assay for bGC and a-galacto-
sidase and the quantitation of tissue glucosylceramide levels were per-
formed using methods described previously (Marshall et al., 2002).
PNGase-F and EndoH treatment of LIMP-2 or bGC were performed
using kits from New England Biolabs (Beverly, MA, USA) and Roche,
respectively.
LIMP-2 siRNA
HeLa cells were transfected with 60 pmol each of LIMP-2-RNAi-
Duplexes SCARB2 Stealth Select 3 RNAi (Invitrogen, Paisley, UK):C50-GAAAGCCAAACUAGGAGACACGAAA-30; 50-CCAAAGAGAGAUG
CAACCUAUUUGU-30; 50-GAUGGAGAGGCUGACAUCAUGAUCA-30
using Lipofectamine 2000 (Invitrogen).
Immunostaining, Immunoprecipitations, Pulse-Chase
Analysis, and Antibodies
The procedures for immunoblotting, coimmunoprecipitation, and
immunostaining of cells grown on coverslips and tissue sections,
pulse-chase analysis in HeLa cells, and all antibodies used in this study
are described in Supplemental Data.
Northern Blotting
Total RNA of kidney, liver, and fibroblasts were prepared using
RNAeasy columns from QIAGEN (Hilden, Germany). Total RNA sam-
ples were separated on an agarose gel and blotted on nylon filters.
Filters were hybridized overnight with a mouse bGC or mouse glycer-
aldehyde dehydrogenase cDNA probe, washed, exposed to an
imaging plate, and developed with the Fuji FLA-5000 phosphoimager
(Fujifilm, Tokyo, Japan).
Mass Spectroscopy
LIMP-2 affinity purified frommurine liver extract was resolved by SDS-
PAGE, stained with Coomassie brilliant blue R-250, excised from the
gel, and in-gel digested with trypsin, and the resulting peptides were
analyzed by nano-LC/MS/MS to obtain peptide sequence data. These
data were used to query the National Center for Biotechnology(E) Immunoblot analysis: MEF cell extracts were treated with EndoH or PNGase-F. The majority of bGC (upper panel) is EndoH resistant in wild-type
MEF cells but EndoH sensitive in LIMP-2/ MEFs. Tubulin loading control (lower panel).
(F) Pulse-chase analysis of bGC expression in metabolically labeled HeLa cells with and without LIMP-2 siRNA treatment. (a) Autoradiograph of bGC
cell-extract immunoprecipitates treatedwith (+) or without () EndoH. (b) Increased secretion of bGCafter 480min of chase in the cell culturemedium.
(c) Quantification of the data presented in (a) and (b). (d and e) Immunofluorescence (d) and immunoprecipitation (e) of LIMP-2 demonstrate it is
downregulated following siRNA treatment.ell 131, 770–783, November 16, 2007 ª2007 Elsevier Inc. 781
Information (Bethesda, MD, USA) nonredundant database using the
Mascot program (Matrix Science, Boston, MA, USA).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and nine figures and can be found with this article online at http://
www.cell.com/cgi/content/full/131/4/770/DC1/.
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